✦ LIBER ✦

Prognostic factors for overall survival in recurrent ovarian, fallopian tube, and peritoneal cancer patients treated with bevacizumab: A multisite study

✍ Scribed by Dao, M.D.; Zsiros, E.; Urban, R.R.; Gray, H.J.; Tamimi, H.K.; Goff, B.A.; Tanyi, J.L.; Liao, J.B.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A prognostic nomogram to predict overall

✍ Previs, R.A.; Bevis, K.S.; Huh, W.; Tillmanns, T.; Perry, L.; Moore, K.; Chapman 📂 Article 📅 2014 🏛 Elsevier Science 🌐 English ⚖ 536 KB

140 Prognostic factors of overall surviv

✍ L. Chaigneau; T. Nguyen; U. Stein; E. Guardiola; A. Danzon; P. Bontemps; X. Pivo 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 168 KB

Determining surrogate endpoints predicti

✍ S. Ueda; A. Alvarez-Secord; W. Huh; T. Tillmanns; K. Moore; R. Previs; L. Perry; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 64 KB

A phase II clinical trial of pegylated l

✍ Marcela G. del Carmen; John Micha; Laurie Small; Daron G. Street; Anil Londhe; T 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 254 KB

Efficacy and safety of bevacizumab plus

✍ Halla S. Nimeiri; Amit M. Oza; Robert J. Morgan; Gregory Friberg; Kristen Kasza; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 256 KB

STAC: A phase II study of carboplatin/pa

✍ S. Campos; T. Atkinson; S. Berlin; M. Roche; C. Whalen; U. Matulonis; N. Horowit 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 48 KB